FR06C0024I2 - Anticorps humanises diriges contre la molecule d'adhesion leucocytaire vla-4 - Google Patents

Anticorps humanises diriges contre la molecule d'adhesion leucocytaire vla-4

Info

Publication number
FR06C0024I2
FR06C0024I2 FR06C0024C FR06C0024C FR06C0024I2 FR 06C0024 I2 FR06C0024 I2 FR 06C0024I2 FR 06C0024 C FR06C0024 C FR 06C0024C FR 06C0024 C FR06C0024 C FR 06C0024C FR 06C0024 I2 FR06C0024 I2 FR 06C0024I2
Authority
FR
France
Prior art keywords
directed against
humanized antibodies
antibodies directed
adhesion molecule
leukocyte adhesion
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR06C0024C
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Athena Neurosciences Inc
Original Assignee
Athena Neurosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Athena Neurosciences Inc filed Critical Athena Neurosciences Inc
Publication of FR06C0024I1 publication Critical patent/FR06C0024I1/fr
Application granted granted Critical
Publication of FR06C0024I2 publication Critical patent/FR06C0024I2/fr
Active legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2842—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta1-subunit-containing molecules, e.g. CD29, CD49
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Pain & Pain Management (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
FR06C0024C 1994-01-25 2006-07-27 Anticorps humanises diriges contre la molecule d'adhesion leucocytaire vla-4 Active FR06C0024I2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US18626994A 1994-01-25 1994-01-25
PCT/US1995/001219 WO1995019790A1 (fr) 1994-01-25 1995-01-25 Anticorps humanises diriges contre la molecule d'adhesion leucocytaire vla-4

Publications (2)

Publication Number Publication Date
FR06C0024I1 FR06C0024I1 (fr) 2006-10-13
FR06C0024I2 true FR06C0024I2 (fr) 2009-01-02

Family

ID=22684288

Family Applications (1)

Application Number Title Priority Date Filing Date
FR06C0024C Active FR06C0024I2 (fr) 1994-01-25 2006-07-27 Anticorps humanises diriges contre la molecule d'adhesion leucocytaire vla-4

Country Status (21)

Country Link
EP (2) EP0804237B8 (fr)
JP (5) JP4115517B2 (fr)
KR (1) KR100367948B1 (fr)
CN (1) CN1211123C (fr)
AT (1) ATE333895T1 (fr)
AU (1) AU703152B2 (fr)
CA (1) CA2182013C (fr)
DE (2) DE69535133T2 (fr)
DK (2) DK1759709T3 (fr)
ES (2) ES2424292T3 (fr)
FI (1) FI117509B (fr)
FR (1) FR06C0024I2 (fr)
HU (1) HU220799B1 (fr)
LU (1) LU91271I2 (fr)
MX (1) MX9602971A (fr)
NL (1) NL300238I2 (fr)
NO (3) NO319867B1 (fr)
NZ (1) NZ279730A (fr)
PL (1) PL181827B1 (fr)
PT (1) PT804237E (fr)
WO (1) WO1995019790A1 (fr)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6307025B1 (en) 1989-04-28 2001-10-23 Biogen, Inc. VCAM fusion proteins and DNA coding therefor
US5871734A (en) * 1992-01-13 1999-02-16 Biogen, Inc. Treatment for asthma with VLA-4 blocking agents
US5932214A (en) 1994-08-11 1999-08-03 Biogen, Inc. Treatment for inflammatory bowel disease with VLA-4 blockers
DK0678122T3 (da) 1993-01-12 2000-03-06 Biogen Inc Rekombinante anti-VLA4 antistofmolekyler
WO1994017828A2 (fr) * 1993-02-09 1994-08-18 Biogen, Inc. Traitement du diabete insulino-dependant
US5840299A (en) * 1994-01-25 1998-11-24 Athena Neurosciences, Inc. Humanized antibodies against leukocyte adhesion molecule VLA-4
US7435802B2 (en) 1994-01-25 2008-10-14 Elan Pharaceuticals, Inc. Humanized anti-VLA4 immunoglobulins
US7750137B2 (en) 1995-09-01 2010-07-06 Millennium Pharmaceuticals, Inc. Mucosal vascular addressins
US6551593B1 (en) 1995-02-10 2003-04-22 Millennium Pharmaceuticals, Inc. Treatment of Inflammatory bowel disease by inhibiting binding and/or signalling through α 4 β 7 and its ligands and madcam
US7803904B2 (en) 1995-09-01 2010-09-28 Millennium Pharmaceuticals, Inc. Mucosal vascular addressing and uses thereof
US7147851B1 (en) * 1996-08-15 2006-12-12 Millennium Pharmaceuticals, Inc. Humanized immunoglobulin reactive with α4β7 integrin
WO1998051345A2 (fr) * 1997-05-09 1998-11-19 The John P. Robarts Research Institute Methode permettant de chasser les leucocytes infiltres dans un tissu
DE19741235A1 (de) 1997-09-18 1999-03-25 Hoechst Marion Roussel De Gmbh Neue Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
DE19741873A1 (de) * 1997-09-23 1999-03-25 Hoechst Marion Roussel De Gmbh Neue 5-Ring-Heterocyclen, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
DE19751251A1 (de) 1997-11-19 1999-05-20 Hoechst Marion Roussel De Gmbh Substituierte Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmezeutische Präparate
DE19821483A1 (de) 1998-05-14 1999-11-18 Hoechst Marion Roussel De Gmbh Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
US7618630B2 (en) 1998-09-14 2009-11-17 Board Of Regents, The University Of Texas System Methods of treating multiple myeloma and myeloma-induced bone resorption using integrin antagonists
EP2065050A1 (fr) * 1998-09-14 2009-06-03 Board of Regents, The University of Texas System Procédés de traitement de myélome multiple et de résorption osseuse liée au myélome utilisant des antagonistes d'intégrine
CN1332714C (zh) 1999-04-22 2007-08-22 比奥根艾迪克Ma公司 整联蛋白α4亚单位的拮抗剂在制备治疗纤维变性的药物组合物中的用途
DE19922462A1 (de) 1999-05-17 2000-11-23 Aventis Pharma Gmbh Spiro-imidazolidinderivate, ihre Herstellung ihre Verwendung und sie enthaltende pharmazeutische Präparate
IL146508A0 (en) 1999-06-01 2002-07-25 Biogen Inc A blocking monoclonal antibody to vla-1 and its use for the treatment of inflammatory disorders
US6949245B1 (en) 1999-06-25 2005-09-27 Genentech, Inc. Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
JP2003517023A (ja) * 1999-12-16 2003-05-20 バイオジェン インコーポレイテッド 中枢神経系の虚血性損傷または出血性損傷を、抗α４インテグリンアンタゴニストを用いて処置する方法
DE10111877A1 (de) 2001-03-10 2002-09-12 Aventis Pharma Gmbh Neue Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
GEP20074252B (en) 2001-04-13 2007-12-10 Biogen Idec Inc Antibodies to vla-1
DE10137595A1 (de) 2001-08-01 2003-02-13 Aventis Pharma Gmbh Neue Imidazolidinderivate, ihre Herstellung und ihre Verwendung
PL215263B1 (pl) 2002-02-25 2013-11-29 Elan Pharm Inc Kompozycja do przewleklego leczenia patologicznego zapalenia i zastosowanie natalizumabu lub jego immunologicznie aktywnego fragmentu do wytwarzania leku
US7371383B2 (en) * 2002-04-12 2008-05-13 Medimmune, Inc. Recombinant anti-interleukin-9 antibodies
GB0210121D0 (en) 2002-05-02 2002-06-12 Celltech R&D Ltd Biological products
TWI323265B (en) * 2002-08-06 2010-04-11 Glaxo Group Ltd Antibodies
CN100432105C (zh) * 2002-12-17 2008-11-12 默克专利有限公司 与gd2结合的小鼠14.18抗体的人源化抗体(h14.18)以及其与il-2的融合
CU23403A1 (es) * 2003-04-23 2009-08-04 Centro Inmunologia Molecular Anticuerpos recombinantes y fragmentos que reconocen el gangliósido n-glicolil gm3 y su uso para diagnóstico y tratamiento de tumores
KR101194176B1 (ko) 2003-12-22 2012-10-24 아지노모토 가부시키가이샤 신규한 페닐알라닌 유도체
CN103169965A (zh) * 2004-11-19 2013-06-26 比奥根艾迪克Ma公司 治疗多发性硬化
JP2009515552A (ja) * 2005-11-17 2009-04-16 ミレニアム・ファーマシューティカルズ・インコーポレイテッド α４β７インテグリン反応性ヒト化免疫グロブリン
MX2008014793A (es) 2006-05-25 2008-12-02 Biogen Idec Inc Metodos para tratar la apoplejia.
EP2124996A4 (fr) 2007-02-20 2010-03-24 Merrimack Pharmaceuticals Inc Méthodes de traitement de la sclérose en plaques par administration d'une alpha-foetoprotéine combinée à un antagoniste de l'intégrine
EP2170390B1 (fr) * 2007-06-14 2018-11-07 Biogen MA Inc. Formulations d'anticorps natalizumab
EP2221325B1 (fr) 2007-12-13 2014-04-16 Tokuyama Corporation Composition photochrome durcissable
CA2721093A1 (fr) 2008-04-11 2009-10-15 Merrimack Pharmaceuticals, Inc. Lieurs d'albumine de serum humain, et ses conjugues
CN103382222B (zh) 2009-03-20 2016-12-28 安姆根有限公司 α-4-β-7异二聚体特异性拮抗剂抗体
WO2011020874A1 (fr) 2009-08-20 2011-02-24 Inserm (Institut National De La Sante Et De La Recherche Medicale) Vla-4 en tant que biomarqueur pour le pronostic et le ciblage pour thérapie dans la dystrophie musculaire de duchenne
SMT202000306T1 (it) 2010-04-16 2020-07-08 Biogen Ma Inc Anticorpi anti-vla-4
UA116189C2 (uk) 2011-05-02 2018-02-26 Мілленніум Фармасьютікалз, Інк. КОМПОЗИЦІЯ АНТИ-α4β7 АНТИТІЛА
DK3311834T3 (da) 2011-05-02 2026-04-20 Millennium Pharmaceuticals Inc Formulering til anti-alfa4beta7-antistof
CA2864539C (fr) 2012-02-16 2022-06-07 Santarus, Inc. Formulations d'anticorps
WO2018002036A1 (fr) 2016-06-28 2018-01-04 Zaklady Farmaceutyczne Polpharma Sa Production recombinante d'anticorps monoclonaux
EP3541413A2 (fr) 2016-11-21 2019-09-25 Polpharma Biologics S.A. Formulations pharmaceutiques aqueuses
DK3583126T3 (da) * 2017-02-17 2025-11-17 Sanofi Sa Multispecifikke bindingsmolekyler med specificitet for dystroglycan og laminin-2
EP3635093A1 (fr) 2017-06-08 2020-04-15 Polpharma Biologics S.A. Méthodes améliorées de culture cellulaire
US12037398B2 (en) 2018-06-04 2024-07-16 Biogen Ma Inc. Anti-VLA-4 antibodies having reduced effector function
US20240301512A1 (en) 2021-01-29 2024-09-12 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods of assessing the risk of developing progressive multifocal leukoencephalopathy in patients treated with vla-4 antagonists

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225539A (en) * 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
IL162181A (en) * 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
IL113261A (en) * 1989-09-01 1996-10-16 Hutchinson Fred Cancer Res Inhibition by peptides of lymphocyte adherence to vascular endothelium utilizing an extracellular matrix receptor-ligand interaction and pharmaceutical compositions containing said peptides
JPH07506566A (ja) * 1992-02-12 1995-07-20 バイオゲン　インコーポレイテッド 炎症性胃腸病の処置
DK0678122T3 (da) * 1993-01-12 2000-03-06 Biogen Inc Rekombinante anti-VLA4 antistofmolekyler
AUPP647298A0 (en) 1998-10-13 1998-11-05 Keystone Retaining Wall Systems, Inc. Retaining wall block

Also Published As

Publication number Publication date
EP0804237A4 (fr) 2003-04-16
DE122006000043I1 (de) 2007-02-15
PL315634A1 (en) 1996-11-25
KR970700513A (ko) 1997-02-12
JPH09508272A (ja) 1997-08-26
ES2270425T3 (es) 2007-04-01
EP1759709B1 (fr) 2013-02-27
NO2017040I1 (no) 2017-08-01
NO2006008I2 (no) 2009-06-15
KR100367948B1 (ko) 2003-07-12
NO2006008I1 (no) 2006-08-07
JP2006045237A (ja) 2006-02-16
EP0804237A1 (fr) 1997-11-05
WO1995019790A1 (fr) 1995-07-27
FR06C0024I1 (fr) 2006-10-13
JP4115517B2 (ja) 2008-07-09
DE69535133D1 (de) 2006-09-07
JP2009235078A (ja) 2009-10-15
FI962958L (fi) 1996-09-24
EP0804237B8 (fr) 2006-11-08
NO319867B1 (no) 2005-09-26
PT804237E (pt) 2006-10-31
NL300238I2 (nl) 2007-05-01
ES2424292T3 (es) 2013-09-30
HUT75129A (en) 1997-04-28
DK0804237T3 (da) 2006-10-16
CA2182013A1 (fr) 1995-07-27
HU9602019D0 (en) 1996-09-30
AU703152B2 (en) 1999-03-18
HU220799B1 (hu) 2002-05-28
MX9602971A (es) 1998-01-31
ATE333895T1 (de) 2006-08-15
FI117509B (fi) 2006-11-15
JP2013173738A (ja) 2013-09-05
NL300238I1 (fr) 2006-10-02
PL181827B1 (pl) 2001-09-28
EP0804237B1 (fr) 2006-07-26
DE69535133T2 (de) 2008-08-21
EP1759709A1 (fr) 2007-03-07
LU91271I2 (fr) 2006-10-02
NO963097D0 (no) 1996-07-24
AU1696095A (en) 1995-08-08
NO963097L (no) 1996-09-24
NO2017040I2 (no) 2018-08-28
CN1211123C (zh) 2005-07-20
FI962958A0 (fi) 1996-07-24
CN1140413A (zh) 1997-01-15
JP5487382B2 (ja) 2014-05-07
NZ279730A (en) 1998-04-27
CA2182013C (fr) 2007-07-17
JP2013165718A (ja) 2013-08-29
DK1759709T3 (da) 2013-06-10

Similar Documents

Publication Publication Date Title
FR06C0024I2 (fr) Anticorps humanises diriges contre la molecule d'adhesion leucocytaire vla-4
FR2735198B1 (fr) Piece d'accastillage de type manille-cosse
DK0739275T3 (da) Fastgørelsesorgan
EP0789579A4 (fr) Composes d'azacyclohexapeptide
EP0999205A4 (fr) Composes d'aminocycloalcane
IT1277973B1 (it) Procedimento per l'assemblaggio di semilavorati per calze-mutanda
ITMI942358A0 (it) Peptidi ad attivita' antiinfiammatoria
NO970463D0 (no) Påföringsbånd for rörledning, uten "primer"
DE69828937D1 (de) Piece d' interposition
IT1313563B1 (it) Testina per l'applicazione di collante in zone prestabilite diprodotti in genere.
ITBO940208A0 (it) Pistola perfezionata per l'applicazione di collante
ITRM950066A0 (it) Procedimento per la produzione di poliammide con aumentata rigidita'.
FR2724251B3 (fr) Structure d'etiquetage
KR960018043U (ko) 체결 부품
IT1290654B1 (it) Stazione per l'applicazione di collante su articoli.
ITMI942219A0 (it) "composti ad attivita' cardiovascolare"
IT242597Y1 (it) L'assorbiumidodeodorante
ITPS940012A0 (it) Giunto di unione, particolarmente indicato per assemblare complementi d'arredo
ITMI940717A0 (it) Composizioni farmaceutiche ad attivita' antitossica
SE9403120D0 (sv) Overall "Easy"
UA680S (uk) Судно-службово-роз'їздне
SE9402579D0 (sv) GB Karlssons märkband
IT234267Y1 (it) Disposizione d'imballaggio per frigoriferi
IT1277010B1 (it) Benzossazinoni ad attivita' antitrombotica
IT232860Y1 (it) macchina per l'applicazione di collante su calzature.